Shire joins orphan disease rush with $500 million Acceleron deal
This article was originally published in Scrip
Executive Summary
Shire has joined the ranks of large pharmaceutical companies pursuing deals and acquisitions in the orphan disease market by acquiring the rights to Acceleron's Duchenne's muscular dystrophy (DMD) treatment ACE-031 outside of North America.